• Bring Clarity to a Complex Disease
  • Advanced technologies to better characterize and assess cancer
GE Healthcare Biopharma Services

Pharma Services

Clarient's BioPharma Services provides expert product development support from discovery through product launch, including research services, biomarker discovery, assay development, clinical trial testing solutions, next generation sequencing, and data analytics.

Learn more 

PATHSiTE™ Virtual HemeFISH

Innovation Powered by Simplicity

PATHSiTE Virtual HemeFISH (VHF)  is the latest innovation in digital pathology services. VHF can help you better interpret, diagnose and report on suspected blood cancers and disorders.

Learn more 


Clarient Diagnostic Services is now part of NeoGenomics Laboratories

 Learn more     Sign up for NeoNews

Now Available for Bladder Cancer

PD-L1, SP142 (FDA)

Ventana PD-L1 (SP142) assay, an FDA-approved complementary diagnostic in metastatic urothelial carcinoma

Indicated as an aid in identifying patients most likely to benefit from TECENTRIQ®

Learn more

Now Available for Melanoma

PD-L1, 28-8 FDA (OPDIVO®)

FDA-approved complementary diagnostic for OPDIVO in NSCLC and melanoma.

Now Available


PD-L1, 22C3 FDA-Approved

PharmDx, approved PD-L1 companion diagnostic for Merck’s Keytruda®
Precise Diagnosis for Precision Lung Cancer Drug

GE Healthcare Press Release  |   Editorial  |   Video Dr. Ken Bloom
Learn more | Merck Keytruda Press Release